Skip to main content
Marksans Pharma Ltd. logo

Marksans Pharma Ltd. — Investor Relations & Filings

Ticker · MARKSANS ISIN · INE750C01026 LEI · 335800YXQPMPSAC51K30 BSE.NS Manufacturing
Filings indexed 727 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country IN India
Listing BSE.NS MARKSANS

About Marksans Pharma Ltd.

https://www.marksanspharma.com

Marksans Pharma Ltd. specializes in the research, development, and large-scale manufacturing of generic formulations. The company’s therapeutic focus spans pain management, cardiovascular health, central nervous system disorders, anti-diabetics, and gastrointestinal treatments. Its product portfolio includes diverse delivery systems such as solid orals, soft gelatin capsules, and liquid formulations, serving both the over-the-counter and prescription markets. The organization operates advanced manufacturing facilities compliant with international regulatory standards, facilitating a robust supply chain across major global markets including North America, Europe, and Australia. By integrating comprehensive research and development with efficient production processes, the company provides a broad range of high-quality, cost-effective medicinal products to a global patient base.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2026-05-19 English
The Company has scheduled a conference call for analysts and investors on Wednesday, May 27, 2026 at 04:30 PM (IST) to discuss the Audited Financial Results (Standalone and Consolidated) ....
Regulatory Filings Classification · 85% confidence The document is a brief notice under SEBI Listing Regulations disclosing the schedule for the Q4FY26 earnings conference call to stock exchanges. It does not contain actual financial results, management discussion, or the call transcript itself, but is a regulatory announcement of an upcoming event. This falls into the catch-all category for miscellaneous regulatory filings rather than an Earnings Release, Transcript, or Presentation.
2026-05-19 English
Disclosure under SEBI Takeover Regulations
Regulatory Filings Classification · 85% confidence The document is a statutory disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations regarding encumbrance of promoters’ shares. It is a compliance filing to the stock exchanges without substantive financial data or being a specific report type. No category for ‘encumbrance’ notifications exists, so it falls under general regulatory filings.
2026-05-19 English
Marksans Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Audited Standalone and Consolidated ....
Board/Management Information Classification · 93% confidence The document is an official intimation to stock exchanges under SEBI Listing Regulations announcing the date and agenda of an upcoming Board of Directors meeting. It does not contain financial results or the minutes of the meeting but rather informs on the board meeting scheduling and related trading window closure. This clearly fits the definition of a Board/Management Information filing (MANG).
2026-05-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-09 English
Press Release
Regulatory Filings
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.